TRANSITION THERAPEUTICS COMPLETES ACQUISITION OF ALZHEIMER'S DISEASE FOCUSED ELLIPSIS NEUROTHERAPEUTICS INC.

Transition Therapeutics Inc. announced today the completion of the acquisition of all remaining outstanding shares of Ellipsis Neurotherapeutics Inc. ("ENI"). The key asset in the acquisition is the Alzheimer's disease compound AZD-103, a disease modifying agent with the potential to both prevent and reduce disease progression, and improve symptoms such as cognitive function.

CNW Group (http://www.newswire.ca/en/releases/archive/March2006/13/c1427.html)